DRUG RECALL TOTALS FOR 2005
This article was originally published in The Gold Sheet
...show the impact of FDA findings of serious GMP and data integrity problems at Able Labs from which the firm could not recover. The recall of all of Able’s marketed products accounted for more than one-sixth of the 254 products called back during the year. FDA cited inadequate oversight by the quality unit and senior management in its findings that Able was not following procedures for release and stability testing and was burying failing results. Contamination-related recalls were up in 2005 as were those given a Class I rating. CBER biological product deviation reports, which may presage recalls, also increased due to more allergenic filings. BPDRs involving product specification deviations continued to predominate while labeling problems doubled. [A nine-page tabulation of drug recalls listed in FDA "Enforcement Reports" during 2005 begins on p. 13.]
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.